Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBR854 cell injection plus docetaxel versus docetaxel in advanced non-small cell lung cancer after failure of first-line standard therapy
CTR20263282Phase 2Active
- Sponsor
- InnoBairui
- Start
- Sep 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IBR854, docetaxel in non-small cell lung cancer (NSCLC), sponsored by InnoBairui. Started Sep 2026; status: active.
02
Drugs
IBR854docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263282.